Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis.
Dihydralazine-induced hepatitis is characterized by the presence of anti-liver microsomal (anti-LM) autoantibodies in the sera of patients. Cytochrome P450 1A2 (CYP1A2), involved in the metabolism of dihydralazine, was shown to be a target for autoantibodies. In order to investigate further the relationship between drug metabolism and the pathogenesis of this drug-induced autoimmune disease, and since the specificity of anti-LM autoantibodies towards CYP1A2 has been determined, the antigenic site was further localized. By constructing fragments derived from CYP1A2 cDNA and probing the corresponding proteins with several anti-LM sera, we were able to define a region (amino acid 335-471) which was immunoreactive with 100% of sera. An internal deletion in this region led to the loss of recognition by anti-LM autoantibodies, confirming that the epitope was conformational. Epitope mapping studies had previously been performed for CYP2D6, CYP17, CYP21A2, and recently for CYP3A1 and CYP2C9. Those data were compared with results obtained in the present study for CYP1A2.
Belloc
C
C
INSERM U75, CHU Necker-Enfants Malades, Université René Descartes, Paris, France.
Gauffre
A
A
André
C
C
Beaune
P H
PH
D000918:Antibody Specificity; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000097:blood / Q000139:chemically induced* / Q000276:immunology; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology / Q000276:immunology*; D019388:Cytochrome P-450 CYP1A2 / Q000276:immunology*; D018076:DNA, Complementary / Q000276:immunology; D004078:Dihydralazine / Q000009:adverse effects* / Q000378:metabolism; D018604:Epitope Mapping; D006801:Humans; D066298:In Vitro Techniques; D008862:Microsomes, Liver / Q000276:immunology
D001323:Autoantibodies; D018076:DNA, Complementary; D019388:Cytochrome P-450 CYP1A2; D004078:Dihydralazine